Preferred Label : Lomvastomig;
NCIt synonyms : Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661; Anti-PD-1/Anti-TIM-3 Bispecific Antibody RO7121661; RO-7121661; Anti-PD-1/TIM-3 Bispecific Antibody RO7121661;
NCIt definition : A bispecific antibody directed against both the negative immunoregulatory human cell
receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell
receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3;
hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory
and antineoplastic activities. Upon administration, lomvastomig simultaneously targets
and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction
of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1
by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates
T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic
T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3,
a transmembrane protein and immune checkpoint receptor, is often co-expressed with
PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3
may enhance T-cell activation and proliferation more than the blockade of either immune
checkpoint receptor alone.;
UNII : 9GAH9VG7IP;
CAS number : 2648840-52-0;
Molecule name : RO7121661; RO 7121661;
NCI Metathesaurus CUI : CL969812;
Origin ID : C160714;
UMLS CUI : C5783377;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
